Jennifer Doudna

Nobel Laureate, Co-Inventor of CRISPR Gene Editing

Health & Well-BeingHealthcare & Healthcare PolicyInnovationInspirational & MotivationalLeadershipSTEMTED SpeakersThought LeadershipWomen LeadersWorld Affairs
Check Availability →

Contact us for Jennifer Doudna's speaking fees and availability

JD

Book Jennifer Doudna through The Keynote Curators, Healthcare Division

Biography

Dr. Jennifer Doudna shared the 2020 Nobel Prize in Chemistry for her co-invention of CRISPR-Cas9, the gene-editing technology that has become a foundational tool in biology, medicine, and agriculture. She is a professor at UC Berkeley, the founder of the Innovative Genomics Institute, and the author of A Crack in Creation, the definitive book on the science and ethics of gene editing.

For pharma leadership boards, biotech investor audiences, hospital innovation programs, and clinical research summits, Jennifer brings something no other speaker can: she is the scientist who actually built the platform that the rest of the industry is now racing to translate into therapies. Her keynotes are uniquely substantive, grounded in primary research rather than secondary commentary, and she is exceptional at translating complex biochemistry for senior business and clinical audiences.

Her current work focuses on the next generation of CRISPR therapeutics, including the recent FDA approvals for sickle-cell disease and beta-thalassemia, the emerging applications in oncology and cardiovascular disease, the agricultural and food-security implications, and the governance and ethics questions that hospital boards and pharma leadership teams are now actively facing.

Jennifer is exceptional for pharma board offsites, biotech investor conferences, hospital innovation summits, and any audience where senior leadership wants a foundational scientific voice rather than a media-first commentator. She is direct, careful, and one of the most carefully prepared speakers on the circuit.

Contact us for Jennifer Doudna's fees and availability →
Speech Topics

What Jennifer Doudna Speaks About

CRISPR, the State of the Field
Where gene editing has actually delivered, where it is still in trials, and where it is heading over the next decade. Built for senior pharma, biotech, and clinical leadership audiences.
The Therapeutics Decade
The first wave of CRISPR therapies has reached patients. The second wave is in trials. The implications for pharma R&D strategy, hospital service-line planning, and payor coverage.
Genomic Medicine for Hospital Leadership
A foundational view of how genomic and gene-editing technologies are reshaping clinical practice, oncology, cardiology, rare disease, and the operational implications for your system.
Ethics, Governance, and the Genome
A direct talk on the scientific, ethical, and governance questions that pharma boards and hospital systems are now actively facing as gene-editing therapies move from the lab to the clinic.
Insights from Jennifer Doudna
play_circle
play_circle
"CRISPR is not a single therapy. It is a platform technology, and the pharma organizations that treat it like a single drug program are going to miss the next decade of the field.", Jennifer Doudna
"The ethical questions in gene editing are not separate from the science. They are part of the science, and they require senior leadership attention now, not after the next clinical headline.", Jennifer Doudna
For meeting planners

Everything You Need to Know

  • Keynote 45 to 60 minutes, scientifically precise, suited to senior leadership audiences.
  • Closed-door board briefing on gene-editing strategy.
  • Fireside chat opposite your CMO, head of R&D, or clinical-trials lead.
  • Moderated panel on therapeutics, ethics, or biotech investing.
  • Wireless lavalier preferred.
  • High-resolution main display for molecular and clinical-trial visuals.
  • Quiet green room for pre-event preparation.
  • Pre-event scoping call with the event chair and a scientific sponsor.
  • Will incorporate your organization's specific therapeutic-area focus into examples.
  • Available for separate scientific-leadership briefing in addition to the main keynote.
  • 6 to 9 months minimum.
  • Annual major-conference dates fill earliest. Lock as soon as you can.
Frequently asked questions

About Booking Jennifer Doudna

What are Dr. Doudna's speaking fees?
Jennifer sits in our top-tier fee range, reflecting her Nobel Laureate status and the foundational nature of her work. Exact figures shared on enquiry. Check availability →
Is Jennifer accessible for non-scientists?
Yes. She is widely regarded as one of the best translators of complex biology for senior business and clinical audiences. Her bestselling book and TED talks are evidence. Check availability →
Does Jennifer do board briefings?
Yes. Closed-door pharma and biotech board sessions are an excellent fit, especially for organizations that need a foundational view of the gene-editing landscape. Check availability →
How far in advance should we book?
6 months minimum, ideally 9 to 12. Jennifer is in extreme demand and her academic schedule is fixed. Check availability →
Book Jennifer Doudna

Interested in Booking Jennifer Doudna for Your Event?

Tell us about your event and we'll get back within 24 hours with availability and pricing.

lock We respond within 24 hours. No spam, ever.

Articles mentioning Jennifer Doudna

From the Blog

April 2026 · 9 min read

25 Hospital CEO and Leadership Speakers Reshaping Healthcare

Twenty-five hospital CEO and system leadership speakers, from former Cleveland Clinic and Intermountain chiefs to…